Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 8월 30

Royalty Pharma PLC

RPRXNASDAQ
Trade with Public
Trade with Public
$60.85
-1.07-1.73%
가까이에: Aug 28, 5:00 PM EST
$60.75
-0.10-0.16%
시간외: Aug 28, 7:14 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황배당금비교옵션주식 보고서

Royalty Pharma Financials

Royalty Pharma (RPRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.28 by 3.13 percent. This is a 15.79 percent increase over earnings of $1.14 per share from the
Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.21 by 7.44 percent. This is a 22.64 percent increase over earnings of $1.06 per share from the
Benzinga Newsdesk

Royalty Pharma Q4 Earnings Report: What Investors Need to Know

Benzinga Insights

PRO
Royalty Pharma Q4 Adj. EPS $1.47 Beats $1.33 Estimate, Sales $622.000M Miss $795.915M Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.33 by 10.86 percent. This is a 26.72 percent increase over earnings of $1.16 per share from the
Benzinga Newsdesk

Earnings Scheduled For February 11, 2026

Benzinga Insights

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved